Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV combination vaccine
- Development stage
- Preclinical
- Lead developer
- Sumagen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HIV combination vaccine (prime-boost) is a preclinical-stage vaccine candidate being developed by Sumagen for the prevention and treatment of HIV/AIDS. The vaccine utilizes a prime-boost strategy designed to induce both humoral and cell-mediated immune responses against HIV. It comprises a combination of an avirulent, non-cytolytic recombinant whole-killed HIV-1 virus (where the natural signal sequence of gp120 is replaced by a non-cytolytic signal sequence, such as honeybee melittin signal peptide) and a recombinant replication-defective adenovirus vector encoding an HIV protein, such as the Gag protein.
- Other names
- HIV Combination Vaccine (prime-boost)Prime-boost HIV Combination Vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)p24 (HIV-1 capsid protein p24)MHC I (MHC class I})γδ TCR (T-cell receptor)HIV (HIV-1 enzymes)
Beyond the preview
Go deeper on HIV combination vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV combination vaccine.